Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner

Cancer Cell

Volumn 10, Issue 4, 2006, Pages 269-280

  Skeen, Jennifer E ^a   Bhaskar, Prashanth T ^a   Chen, Chia Chen ^a   Chen, William S ^a   Peng, Xiao ding ^a   Nogueira, Veronique ^a   Hahn Windgassen, Annett ^a   Kiyokawa, Hiroaki ^b   Hay, Nissim ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

CELLCYCLE; RNA; SIGNALING

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN P53;

AKT PROTEIN DEFICIENCY; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER SUSCEPTIBILITY; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; GENE DELETION; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN CARCINOGENESIS;

MOUSE MAMMARY TUMOR VIRUS;

EID: 33749430399     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2006.08.022     Document Type: Article

References (42)

1. Aoki M., Batista O., Bellacosa A., Tsichlis P., and Vogt P.K. The akt kinase: Molecular determinants of oncogenicity. Proc. Natl. Acad. Sci. USA 95 (1998) 14950-14955
2. Chen W.S., Xu P.Z., Gottlob K., Chen M.L., Sokol K., Shiyanova T., Roninson I., Weng W., Suzuki R., Tobe K., et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 15 (2001) 2203-2208
3. Chen M.L., Xu P.Z., Peng X., Chen W.S., Guzman G., Yang X., Di Cristofano A., Pandolfi P.P., and Hay N. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev. 20 (2006) 1569-1574
4. Di Cristofano A., Pesce B., Cordon-Cardo C., and Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19 (1998) 348-355
5. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3 (2003) 11-22
6. Fingar D.C., Richardson C.J., Tee A.R., Cheatham L., Tsou C., and Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 24 (2004) 200-216
7. Gera J.F., Mellinghoff I.K., Shi Y., Rettig M.B., Tran C., Hsu J.H., Sawyers C.L., and Lichtenstein A.K. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J. Biol. Chem. 279 (2004) 2737-2746
8. Gingras A.C., Kennedy S.G., O'Leary M.A., Sonenberg N., and Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 12 (1998) 502-513
9. Hahn-Windgassen A., Nogueira V., Chen C.C., Skeen J.E., Sonenberg N., and Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J. Biol. Chem. 280 (2005) 32081-32089
10. Harada H., Andersen J.S., Mann M., Terada N., and Korsmeyer S.J. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. USA 98 (2001) 9666-9670
11. Harrington L.S., Findlay G.M., and Lamb R.F. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem. Sci. 30 (2005) 35-42
12. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8 (2005) 179-183
13. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 18 (2004) 1926-1945
14. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., and Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4 (2005) 988-1004
15. Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4 (2002) 648-657
16. Kang S., Bader A.G., and Vogt P.K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. USA 102 (2005) 802-807
17. Lawlor M.A., and Alessi D.R. PKB/Akt: A key mediator of cell proliferation, survival and insulin responses?. J. Cell Sci. 114 (2001) 2903-2910
18. Li Y., Inoki K., and Guan K.L. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol. Cell. Biol. 24 (2004) 7965-7975
19. Luo Y., Marx S.O., Kiyokawa H., Koff A., Massague J., and Marks A.R. Rapamycin resistance tied to defective regulation of p27kip1. Mol. Cell. Biol. 12 (1996) 6744-6751
20. Majumder P.K., Yeh J.J., George D.J., Febbo P.G., Kum J., Xue Q., Bikoff R., Ma H., Kantoff P.W., Golub T.R., et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model. Proc. Natl. Acad. Sci. USA 100 (2003) 7841-7846
21. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., and Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10 (2002) 151-162
22. Manning B.D., Logsdon M.N., Lipovsky A.I., Abbott D., Kwiatkowski D.J., and Cantley L.C. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev. 19 (2005) 1773-1778
23. Mayo L.D., and Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA 98 (2001) 11598-11603
24. Parsons R., and Simpson L. PTEN and cancer. Methods Mol. Biol. 222 (2003) 147-166
25. Peng X.D., Xu P.Z., Chen M.L., Hahn-Windgassen A., Skeen J., Jacobs J., Sundararajan D., Chen W.S., Crawford S.E., Coleman K.G., and Hay N. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 17 (2003) 1352-1365
26. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., Cordon-Cardo C., Catoretti G., Fisher P.E., and Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA 96 (1999) 1563-1568
27. Rajasekhar V.K., Viale A., Socci N.D., Wiedmann M., Hu X., and Holland E.C. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol. Cell 12 (2003) 889-901
28. Robey R.B., and Hay N. Mitochondrial hexokinases: Guardians of the mitochondria. Cell Cycle 4 (2005) 654-658
29. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
30. Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 22 (2004) 2954-2963
31. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
32. Schmidt M., Fernandez de Mattos S., van der Horst A., Klompmaker R., Kops G.J., Lam E.W., Burgering B.M., and Medema R.H. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol. Cell. Biol. 22 (2002) 7842-7852
33. Sinn E., Muller W., Pattengale P., Tepler I., Wallace R., and Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell 49 (1987) 465-475
34. Stahl M., Dijkers P.F., Kops G.J., Lens S.M., Coffer P.J., Burgering B.M., and Medema R.H. The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J. Immunol. 168 (2002) 5024-5031
35. Suzuki A., de la Pompa J.L., Stambolic V., Elia A.J., Sasaki T., del Barco Barrantes I., Ho A., Wakeham A., Itie A., Khoo W., et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8 (1998) 1169-1178
36. Thomas G.V. mTOR and cancer: Reason for dancing at the crossroads?. Curr. Opin. Genet. Dev. 16 (2006) 78-84 10.1016/j.gde.2005.12.003 Published online December 15, 2005
37. Wyszomierski S.L., and Yu D. A knotty turnabout?: Akt1 as a metastasis suppressor. Cancer Cell 8 (2005) 437-439
38. Yu Q., Geng Y., and Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 411 (2001) 1017-1021
39. Zhang H., Stallock J.P., Ng J.C., Reinhard C., and Neufeld T.P. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev. 14 (2000) 2712-2724
40. Zhang H., Cicchetti G., Onda H., Koon H.B., Asrican K., Bajraszewski N., Vazquez F., Carpenter C.L., and Kwiatkowski D.J. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 112 (2003) 1223-1233
41. Zhou B.P., Liao Y., Xia W., Zou Y., Spohn B., and Hung M.C. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3 (2001) 973-982
42. Zou X., Ray D., Aziyu A., Christov K., Boiko A.D., Gudkov A.V., and Kiyokawa H. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev. 16 (2002) 2923-2934